Antiangiogenic agents: current limits in thoracic oncology

被引：0
|
作者：
Dansin, Eric [1 ]
Lauridant, Geraldine [1 ]
Chahine, Bachar [1 ]
机构：
[1] CLCC Oscar Lambret, Dept Cancerol Gen, F-59020 Lille, France
来源：
BULLETIN DU CANCER | 2012年 / 99卷 / 11期
关键词：
antiangiogenic agent; multi-targeted tyrosine kinase inhibitor; bevacizumab; lung cancer; thoracic oncology; CELL-LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED PHASE-II; ANGIOGENESIS INHIBITOR BEVACIZUMAB; ARTERIAL THROMBOEMBOLIC EVENTS; PACLITAXEL PLUS BEVACIZUMAB; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; COST-EFFECTIVENESS; 1ST-LINE BEVACIZUMAB;
D O I：
10.1684/bdc.2012.1655
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.
引用
收藏
页码：1083 / 1091
页数：9
相关论文
共 50 条
  • [41] Novel antiangiogenic agents for use in contraception
    Sharkey, AM
    Catalano, R
    Evans, A
    Charnock-Jones, DS
    Smith, SK
    CONTRACEPTION, 2005, 71 (04) : 263 - 271
  • [42] Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology
    Bertolini, Francesco
    BREAST, 2009, 18 : S48 - S50
  • [43] News in thoracic oncology
    Vignot, S.
    Besse, B.
    ONCOLOGIE, 2008, 10 (7-8) : 467 - 471
  • [44] Thoracic surgical oncology
    Kuntz, CA
    CLINICAL TECHNIQUES IN SMALL ANIMAL PRACTICE, 1998, 13 (01): : 47 - 52
  • [45] The future of thoracic oncology
    Pego-Fernandes, Paulo M.
    Dela Vega, Alberto J. M.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2016, 62 (01): : 1 - 3
  • [46] Reviews in thoracic oncology
    Kanellakis, Nikolaos I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Controversies in Thoracic Oncology
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 366 - 367
  • [48] Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
    Li, Shu-Jin
    Chen, Jia-Xian
    Sun, Zhi-Jun
    CANCER COMMUNICATIONS, 2021, 41 (09) : 830 - 850
  • [49] Cutaneous side effects of antiangiogenic agents
    Robert, Caroline
    BULLETIN DU CANCER, 2007, 94 : S260 - S264
  • [50] Radiation combined with antiangiogenic and antivascular agents
    O'Reilly, MS
    SEMINARS IN RADIATION ONCOLOGY, 2006, 16 (01) : 45 - 50
12345